サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1263963

リキッドバイオプシーの世界市場：市場規模、動向、成長分析（2022年～2027年）

Liquid Biopsy Market: Market Size, Trends and Growth Analysis [2022-2027]
出版日: | 発行: Lucintel | ページ情報: 英文 264 Pages | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

リキッドバイオプシーの世界市場：市場規模、動向、成長分析（2022年～2027年）
出版日: 2023年02月01日
発行: Lucintel
ページ情報: 英文 264 Pages
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界のリキッドバイオプシーの市場規模は、2027年までに86億米ドルに達し、2022年～2027年にCAGRで14.5%の成長が予測されています。市場の主な促進要因は、がんの流行や、非侵襲的な処置への選好、高精度な疾患のリアルタイムでの早期発見に対するニーズの増加です。

当レポートでは、世界のリキッドバイオプシー市場について調査分析し、動向と予測、成長機会の分析、企業プロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 世界のリキッドバイオプシー市場の背景と分類

  • イントロダクション、背景および分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 市場動向と予測分析（2015年～2026年）

  • マクロ経済の動向と予測
  • 世界のリキッドバイオプシー市場の動向と予測
  • 世界のリキッドバイオプシー市場：製品別
    • アッセイキット
    • 器具
    • サービス
  • 世界のリキッドバイオプシー市場：循環バイオマーカー別
    • 循環腫瘍細胞（CTC）
    • 循環腫瘍DNA（ctDNA）
    • 無細胞DNA（cfDNA）
    • 細胞外小胞（EV）
    • その他の循環バイオマーカー
  • 世界のリキッドバイオプシー市場：用途別
    • がん
      • 肺がん
      • 乳がん
      • 大腸がん
      • 前立腺がん
      • 肝臓がん
      • その他のがん
    • 非がん
  • 世界のリキッドバイオプシー市場：臨床応用別
    • 早期がんのスクリーニング
    • 治療法の選択
    • 治療モニタリング
    • 再発モニタリング
  • 世界のリキッドバイオプシー市場：エンドユーザー別
    • レファレンスラボラトリー
    • 病院、医師の研究所
    • 学術、研究センター
    • その他のエンドユーザー

第4章 市場動向と予測分析（2015年～2026年）

  • 世界のリキッドバイオプシー市場：地域別
  • 北米のリキッドバイオプシー市場の動向と予測
    • 北米のリキッドバイオプシー市場：製品別
    • 北米のリキッドバイオプシー市場：循環バイオマーカー別
    • 北米のリキッドバイオプシー市場：用途別
    • 北米のリキッドバイオプシー市場：臨床応用別
    • 北米のリキッドバイオプシー市場：最終用途別
    • 米国のリキッドバイオプシー市場
    • カナダのリキッドバイオプシー市場
    • メキシコのリキッドバイオプシー市場
  • 欧州のリキッドバイオプシー市場の動向と予測
    • 欧州のリキッドバイオプシー市場：製品別
    • 欧州のリキッドバイオプシー市場：循環バイオマーカー別
    • 欧州のリキッドバイオプシー市場：用途別
    • 欧州のリキッドバイオプシー市場：臨床応用別
    • 欧州のリキッドバイオプシー市場：最終用途別
    • 英国のリキッドバイオプシー市場
    • ドイツのリキッドバイオプシー市場
    • フランスのリキッドバイオプシー市場
    • イタリアのリキッドバイオプシー市場
    • スペインのリキッドバイオプシー市場
  • アジア太平洋のリキッドバイオプシー市場の動向と予測
    • アジア太平洋のリキッドバイオプシー市場：製品別
    • アジア太平洋のリキッドバイオプシー市場：循環バイオマーカー別
    • アジア太平洋のリキッドバイオプシー市場：用途別
    • アジア太平洋のリキッドバイオプシー市場：臨床応用別
    • アジア太平洋のリキッドバイオプシー市場：最終用途別
    • 日本のリキッドバイオプシー市場
    • 中国のリキッドバイオプシー市場
    • インドのリキッドバイオプシー市場
  • その他の地域のリキッドバイオプシー市場の動向と予測
    • その他の地域のリキッドバイオプシー市場：製品別
    • その他の地域のリキッドバイオプシー市場：循環バイオマーカー別
    • その他の地域のリキッドバイオプシー市場：用途別
    • その他の地域のリキッドバイオプシー市場：臨床応用別
    • その他の地域のリキッドバイオプシー市場：最終用途別
    • ブラジルのリキッドバイオプシー市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 市場シェア分析
  • 経営の統合
  • 地理的リーチ
  • ポーターのファイブフォース分析

第6章 成長機会と戦略の分析

  • 成長機会の分析
    • 世界のリキッドバイオプシー市場の成長機会：製品別
    • 世界のリキッドバイオプシー市場の成長機会：循環バイオマーカー別
    • 世界のリキッドバイオプシー市場の成長機会：用途別
    • 世界のリキッドバイオプシー市場の成長機会：臨床応用別
    • 世界のリキッドバイオプシー市場の成長機会：最終用途別
    • 世界のリキッドバイオプシー市場の成長機会：地域別
  • 世界のリキッドバイオプシー市場における新たな動向
  • 戦略の分析
    • 新製品の開発
    • ライセンシングと認証
    • 世界のリキッドバイオプシー市場における合併、買収、合弁事業、その他の提携

第7章 主要企業の企業プロファイル

  • Bio-Rad Laboratories
  • QIAGEN
  • MDxHealth
  • Myriad Genetics
  • Biocept, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Cardiff Oncology
  • Guardant Health
目次

Liquid Biopsy Market Trends and Forecast

The future of the global liquid biopsy market looks promising with opportunities in reference laboratories, hospitals and physician laboratories, and academic and research centers. The global liquid biopsy market is expected to reach an estimated $8.6 billion by 2027 with a CAGR of 14.5% from 2022 to 2027. The major drivers for this market are the increasing prevalence of cancer, preference for non-invasive procedures, and increasing need of early detection of high precision diseases in real time.

Emerging Trends in Liquid Biopsy Market

Emerging trends, which have a direct impact on the dynamics of the industry, include the usage of methylation-specific polymerase chain reaction (MS-PCR) liquid biopsy technology and the emergence of hybrid ctDNA and CTC target selector.

A total of 163 figures / charts and 129 tables are provided in this 264-page report to help in your business decisions. Sample figures with some insights are shown below.

Liquid Biopsy Market by Segment

In this market, therapy selection is the largest clinical application market, and circulating tumor DNA is the largest circulating biomarker segment. Growth in various segments of the liquid biopsy market are shown in the figure below.

The study includes trends and forecast for the global liquid biopsy market by product, circulating biomarker, application, clinical application, end use, and region as follows:

Liquid Biopsy Market by Product [Value ($M) from 2016 to 2027]:

  • Assays Kits
  • Instruments
  • Services

Liquid Biopsy Market by Circulating Biomarker [Value ($M) from 2016 to 2027]:

  • Circulating Tumor Cells (CTCs)
  • Circulating Tumor DNA (CtDNA)
  • Cell-Free DNA (cfDNA)
  • Extracellular Vesicles (EVs)
  • Other Biomarkers

Liquid Biopsy Market by Application [Value ($M) from 2016 to 2027]:

  • Oncology

Lung Cancer

Breast Cancer

Colorectal Cancer

Prostate Cancer

Liver Cancer

Other Cancers

  • Non-Cancer

Liquid Biopsy Market by Clinical Application [Value ($M) from 2016 to 2027]:

  • Early Cancer Screening
  • Therapy Selection
  • Treatment Monitoring
  • Recurrence Monitoring

Liquid Biopsy Market by End Use [Value ($M) from 2016 to 2027]:

  • Reference Laboratories
  • Hospitals and Physician Laboratories
  • Academic and Research Centers
  • Other End Uses

Liquid Biopsy Market by Region [Value ($M) from 2016 to 2027]:

  • North America

US

Canada

Mexico

  • Europe

United Kingdom

France

Germany

Italy

Spain

  • APAC

China

Japan

India

  • ROW

Brazil

List of Liquid Biopsy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, liquid biopsy companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the liquid biopsy companies profiled in this report include-

  • Guardant
  • Bio-Rad Laboratories
  • Qiagen
  • MDxHealth
  • Myriad Genetics
  • Biocept
  • Roche
  • Illumina
  • Thermofisher

Liquid Biopsy Market Insights

  • Lucintel forecasts circulating tumor DNA will remain the largest segment and is also expected to witness the highest growth over the forecast period due to increasing use of ctDNA biomarkers in next-generation sequencing (NGS) technologies for detecting diseases in real time and in early stage.
  • Therapy selection will remain the largest clinical application over the forecast period due to its offerings of various benefits, such as non-invasiveness, access to tumor heterogeneity, real-time treatment monitoring, and recurrence detection in advance of significant tumor formation or metastasis.
  • APAC will remain the fastest growing region over the forecast period due to rising non-invasive treatment, a rising incidence of cancer, and improving healthcare infrastructure.

Features of the Global Liquid Biopsy Market

  • Market Size Estimates: Global liquid biopsy market size estimation in terms of value ($B) shipment.
  • Trend and Forecast Analysis: Market trends (2016-2021) and forecast (2022-2027) by various segments.
  • Segmentation Analysis:Global liquid biopsy market size by product, circulating biomarker, application, clinical application, end use, and region in terms of value.
  • Regional Analysis: Global liquid biopsy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different by product, circulating biomarker, application, clinical application, end use, and region for the global liquid biopsy market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global liquid biopsy market.
  • Analysis of competitive intensity of the industry based on Porter's Five Forces model

FAQ

Q1. What is theliquid biopsy marketsize?

Answer:The global liquid biopsy market is expected to reach an estimated $10.4 billion by 2026.

Q2. What is the growth forecast for theliquid biopsy market?

Answer:The global liquid biopsy market is expected to grow at a CAGR of ~17% from 2020 to 2026.

Q3. What are the major drivers influencing the growth of theliquid biopsy market?

Answer: The major drivers for this market are increasing prevalence of cancer, preference for non-invasive procedures, and increasing need for early detection of high precision diseases in real time.

Q4. What are the major clinical applications of theliquid biopsy market?

Answer:Early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring are the major clinical application segments of liquid biopsy.

Q5. What are the emerging trends in theliquid biopsy market?

Answer:Emerging trends, which have a direct impact on the dynamics of the industry, include the usage of methylation-specific polymerase chain reaction (MS-PCR) liquid biopsy technology and the emergence of hybrid ctDNA and CTC target selector.

Q6. Who are the keyliquid biopsy companies?

Answer:Some of the key liquid biopsy companies are as follows:

  • Guardant
  • Bio-Rad Laboratories
  • Qiagen
  • MDxHealth
  • Myriid Genetics
  • Biocept
  • Roche
  • Illumina
  • Thermofisher

Q7.Which will be the largestcirculating biomarker segment of theliquid biopsy marketin the future?

Answer: Lucintel forecasts that circulating tumor DNA (ctDNA) will remain the largest segment, and it is also expected to witness the highest growth over the forecast period due to increasing use of ctDNA biomarkers in next-generation sequencing (NGS) technologies for detecting diseases in real time and in the early stage.

Q8: Inliquid biopsy market, which region is expected to be the largest in the next five years?

Answer:Asia Pacific is expected to be the largest region over the next five years.

Q9. Do we receive customization in this report?

Answer:Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions

  • Q.1 What are some of the most promising growth opportunities for the global liquid biopsy market by product (assay kits, instruments, and services), circulating biomarker (circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other biomarkers), application (oncology and non-cancer liquid biopsies), clinical application (early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring), end use (reference laboratories, hospitals and physician laboratories, academic and research centers, and other end uses), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2 Which segments will grow at a faster pace and why?
  • Q.3 Which region will grow at a faster pace and why?
  • Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global liquid biopsy market?
  • Q.5 What are the business risks and threats to the global liquid biopsy market?
  • Q.6 What are the emerging trends in this liquid biopsy market and the reasons behind them?
  • Q.7 What are some changing demands of customers in the liquid biopsy market?
  • Q.8 What are the new developments in the liquid biopsy market? Which companies are leading these developments?
  • Q.9 Who are the major players in the liquid biopsy market? What strategic initiatives are being implemented by key players for business growth?
  • Q.10 What are some of the competitive products and processes in the liquid biopsy market, and how big of a threat do they pose for loss of market share via material or product substitution?
  • Q.11 What M&A activities did take place in the last five years in the global liquid biopsy market?

Table of Contents

1. Executive Summary

2. Global Liquid Biopsy Market Background and Classifications

  • 2.1: Introduction, Background and Classification
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2015 to 2026

  • 3.1: Macroeconomic Trends and Forecasts
  • 3.2: Global Liquid Biopsy Market Trends and Forecast
  • 3.3: Global Liquid Biopsy Market by Product
    • 3.3.1: Assay Kits
    • 3.3.2: Instruments
    • 3.3.3: Services
  • 3.4: Global Liquid Biopsy Market by Circulating Biomarker
    • 3.4.1: Circulating Tumor Cells (CTCs)
    • 3.4.2: Circulating Tumor DNA (ctDNA)
    • 3.4.3: Cell-Free DNA (cfDNA)
    • 3.4.4: Extracellular Vesicles (EVs)
    • 3.4.5: Other Circulating Biomarkers
  • 3.5: Global Liquid Biopsy Market by Application
    • 3.5.1: Oncology
      • 3.5.1.1: Lung Cancer
      • 3.5.1.2: Breast Cancer
      • 3.5.1.3: Colorectal Cancer
      • 3.5.1.4: Prostate Cancer
      • 3.5.1.5: Liver Cancer
      • 3.5.1.6: Other Cancer
    • 3.5.2: Non-Cancer
  • 3.6: Global Liquid Biopsy Market by Clinical Application
    • 3.6.1: Early Cancer Screening
    • 3.6.2: Therapy Selection
    • 3.6.3: Treatment Monitoring
    • 3.6.4: Recurrence Monitoring
  • 3.7: Global Liquid Biopsy Market by End User
    • 3.7.1: Reference Laboratories
    • 3.7.2: Hospitals and Physician Laboratories
    • 3.7.3: Academic and Research Centers
    • 3.7.4: Other End Users

4. Market Trends and Forecast Analysis from 2015 to 2026

  • 4.1: Global Liquid Biopsy Market by Region
  • 4.2: North American Liquid Biopsy Market Trends and Forecast
    • 4.2.1: North American Liquid Biopsy Market by Product
    • 4.2.2: North American Liquid Biopsy Market by Circulating Biomarker
    • 4.2.3: North American Liquid Biopsy Market by Application
    • 4.2.4: North American Liquid Biopsy Market by Clinical Application
    • 4.2.5: North American Liquid Biopsy Market by End Use
    • 4.2.6: United States Liquid Biopsy Market
    • 4.2.7: Canadian Liquid Biopsy Market
    • 4.2.8: Mexican Liquid Biopsy Market
  • 4.3: European Liquid Biopsy Market Trends and Forecast
    • 4.3.1: European Liquid Biopsy Market by Product
    • 4.3.2: European Liquid Biopsy Market by Circulating Biomarker
    • 4.3.3: European Liquid Biopsy Market by Application
    • 4.3.4: European Liquid Biopsy Market by Clinical Application
    • 4.3.5: European Liquid Biopsy Market by End Use
    • 4.3.6: United Kingdom Liquid Biopsy Market
    • 4.3.7: German Liquid Biopsy Market
    • 4.3.8: French Liquid Biopsy Market
    • 4.3.9: Italian Liquid Biopsy Market
    • 4.3.10: Spanish Liquid Biopsy Market
  • 4.4: APAC Liquid Biopsy Market Trends and Forecast
    • 4.4.1: APAC Liquid Biopsy Market by Product
    • 4.4.2: APAC Liquid Biopsy Market by Circulating Biomarker
    • 4.4.3: APAC Liquid Biopsy Market by Application
    • 4.4.4: APAC Liquid Biopsy Market by Clinical Application
    • 4.4.5: APAC Liquid Biopsy Market by End Use
    • 4.4.6: Japanese Liquid Biopsy Market
    • 4.4.7: Chinese Liquid Biopsy Market
    • 4.4.8: Indian Liquid Biopsy Market
  • 4.5: ROW Liquid Biopsy Market Trends and Forecast
    • 4.5.1: ROW Liquid Biopsy Market by Product
    • 4.5.2: ROW Liquid Biopsy Market by Circulating Biomarker
    • 4.5.3: ROW Liquid Biopsy Market by Application
    • 4.5.4: ROW Liquid Biopsy Market by Clinical Application
    • 4.5.5: ROW Liquid Biopsy Market by End Use
    • 4.5.6: Brazilian Liquid Biopsy Market

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Market Share Analysis
  • 5.3: Operational Integration
  • 5.4: Geographical Reach
  • 5.5: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Liquid Biopsy Market by Product
    • 6.1.2: Growth Opportunities for the Global Liquid Biopsy Market by Circulating Biomarker
    • 6.1.3: Growth Opportunities for the Global Liquid Biopsy Market by Application
    • 6.1.4: Growth Opportunities for the Global Liquid Biopsy Market by Clinical Application
    • 6.1.5: Growth Opportunities for the Global Liquid Biopsy Market by End Use
    • 6.1.6: Growth Opportunities for the Global Liquid Biopsy Market by Region
  • 6.2: Emerging Trends in the Global Liquid Biopsy Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Licensing and Certification
    • 6.3.3: Mergers, Acquisitions, Joint Ventures, and Other Collaborations in the Global Liquid Biopsy Market

7. Company Profiles of Leading Players

  • 7.1: Bio-Rad Laboratories
  • 7.2: QIAGEN
  • 7.3: MDxHealth
  • 7.4: Myriad Genetics
  • 7.5: Biocept, Inc.
  • 7.6: F. Hoffmann-La Roche Ltd.
  • 7.7: Thermo Fisher Scientific Inc.
  • 7.8: Illumina, Inc.
  • 7.9: Cardiff Oncology
  • 7.10: Guardant Health